臺灣博碩士論文加值系統

基因的遺傳多型性對於腫瘤的發生和預防扮演一個重要的角色。亞甲基四氫葉酸還原酶的多型性和某些種類癌症發生的風險率有關，但是其機制仍然需要進一步的研究。 亞甲基四氫葉酸還原酶催化 5,10-亞甲基四氫葉酸的還原反應，而這個反應的產物為 5-甲基四氫葉酸。 5-甲基四氫葉酸可以提供甲基給同半胱胺酸，使同半胱胺酸轉變成甲硫胺酸。已知亞甲基四氫葉酸還原酶多型性中TT同型合子的會導致酵素活性的下降並且改變細胞內葉酸形式的組成。在本研究論文裡，我們研究此葉酸形式的重新分配是否會導致同半胱胺酸的再甲基化下降或/且提高嘌呤或胸腺嘧啶的生合成作用；而DNA甲基化及核酸生合成的調控和腫瘤的發生機制有密切關係。我們利用表現不同亞甲基四氫葉酸還原酶多型性的淋巴母細胞來研究同半胱胺酸的再甲基化和嘌呤及胸腺嘧啶的生合成作用及代謝改變情形。在不同的營養狀態下，以特定之穩定同位素分別追蹤代謝路徑，並利用氣相層析質譜儀來測定胞內胺基酸和核苷酸代謝路徑的變化。我們數據指出在細胞內葉酸充足情形之下，亞甲基四氫葉酸還原酶的基因多型性並不會影響依賴葉酸的同半胱胺酸再甲基化相對流量。 但在細胞內葉酸不充足的情形之下，亞甲基四氫葉酸還原酶基因突變型其同半胱胺酸(葉酸依賴的)再甲基化的代謝會顯著較正常型來的低；推測可能是因為甲基化形式的葉酸來源受到限制。 當葉酸狀態充足的情形之下，亞甲基四氫葉酸還原酶基因突變型細胞的嘌呤的生合成作用其相對流量顯著較正常型為高；推測可能是因為可被利用的甲醯化型式的葉酸增加的緣故。 然而當葉酸不充足時，兩個基因型之間的嘌呤的生合成作用似乎並無不同；推測突變型細胞其嘌呤生合成的優勢只有在葉酸充足的情形之下才存在。我們的數據亦顯示出亞甲基四氫葉酸還原酶基因的多型性的影響和葉酸營養狀態有密切的關係，此種關係因而可能會影響和疾病發生及蔓延過程中相關代謝途徑的調控。亞甲基四氫葉酸還原酶基因突變型細胞的嘌呤生合成作用的優勢或許可以解釋何以在某些流行病學研究顯示此種基因型可降低某些癌症發生的風險，即此種基因型對於某些癌症發生具保護作用，但在其他的情形下如葉酸營養狀態不理想時，反而觀察到其可能有增加癌症發生風險。本論文提出此細胞模型，以研究人類亞甲基四氫葉酸還原酶基因變異和癌症發生及與營養狀況交互作用的相關代謝途徑。　

Genetic predisposition plays a significant role in tumorigenesis and cancer prevention. A common polymorphism 677C->T in methylenetetrahydrofolate reductase (MTHFR) is associated with altered risk of certain types of cancer, but the mechanism remains to be determined. MTHFR catalyzes the reduction of 5, 10-methylene- tetrahydrofolate to 5-methyltetrahydrofolate, the methyl donor for the synthesis of methionine from homocysteine. The homozygous C677T mutation in the MTHFR gene results in reduction in enzyme activity and changes in cellular distribution of folates. In the present study we investigate if the folate form redistribution results in compromised homocysteine remethylation and elevated de novo purine synthesis, both of which may be potential regulatory pathways involved in tumorigenesis. Metabolic fluxes of homocysteine remethylation and de novo purine synthesis were studied in Epstein-Barr virus transformed lymphoblasts expressing common polymorphic allele 677 C and 677T of the MTHFR gene. Using different stable isotopic tracers, specific enrichments in intracellular amino acid pool and nucleotides were measured by Gas Chromatography /Mass Spectrometry under various nutritional conditions. Our preliminary data indicated that when cellular folate was adequate, the MTHFR genotype did not affect the folate dependent homocysteine remethylation pathways (relative enrichments of methionine m+1 specie labeled from 13C-serine tracer in CC vs. TT=0.45 + 0.28 vs. 0.40 + 0.11, p=0.83). Only when cells became folate deficient, the folate dependent remethylation pathway in TT genotype was significantly reduced compared to the CC genotypes (CC vs. TT = 0.048 + 0.011 vs. 0.008 + 0.006, p=0.043), presumably due to limited methylated folates. Using 13C-serine as the tracer, de novo purine synthesis in TT genotype was found to be elevated when folate status is adequate (relative enrichments in the purine +1 specie in CC vs. TT = 0.48 + 0.11 vs. 0.71 + 0.06, p<0.0001), presumably due to increased availability of formylated folates. When folate was restricted, no difference in purine synthesis was found between the 2 genotypes, suggesting that the advantage in purine synthesis only exists when folate supply is adequate. Our data suggest that the impacts of MTHFR 677T polymorphism are closely related to nutritional conditions, and such alterations may modulate metabolic pathways involved in disease onset/progression. The advantage of de novo purine synthesis found in the MTHFR TT genotype may account for the protective effect of MTHFR in certain type of cancers. These transformed cells are potential models for studying the consequences of human genetic variation in MTHFR and their relationship to pathways involved in cancer pathogenesis or progression.

List of abbreviations……………………………...………………………...4
中文摘要 ....................................................................................................5
ABSTRACT …………………………………………………………..…..7
BACKGROUND AND SIGNIFICANCE…………………………………………..9
HYPOTHESIS………………………………………………………………………15
OBJECTIVE AND SPECIFIC AIMS............................................................17
MATERIALS AND METHODS…………………………………………………...18
RESULTS……………………………………………………………………………25
DISCUSSIONS……………………………………………………………………...36

FIGURES
Figure 1. The genotypes of MTHFR and thymidine synthase in transformed lymphoblasts………………………………………………………............53

Figure 2. Growth curves of transformed lymphoblasts expressing MTHFR CC and TT genotype under high folate and low folate status………………………….54

Figure 3. The effects of 5-FU and MTX on [H3 ]thymidine incorporation in transformed lymphoblasts…………………………………………………………….....55

Figure 4. The effect of MTHFR polymorphism on chemosensitivity to 5-FU and MTX in lymphoblasts…………………………………………………………….56

Figure 5. The effect of thymidylate synthase tandem repeat polymorphism on chemosensitivity to 5-FU and MTX in lymphoblasts……………………...57

Figure 6. The effect of MTHFR polymorphisms on chemosensitivity to 5-FU + leucovorin and MTX + leucovorin ………………………………………...58

Figure 7. The effect of thymidylate synthase tandem repeat polymorphism on chemosensitivity to 5-FU + leucovorin and MTX + leucovorin………...…59

TABLES
Table 1. Effect of the MTHFR 677T mutation on the M+1 enrichments in nucleotides from [13C] - labeled serine precursor in high folate status…………………..60

Table 2. Effect of MTX and MTHFR 677T mutation on the enrichments in DNA nucleotides from [13C] - labeled serine precursor in transformed lymphoblasts………………………………………………………………...61

Table 3. Effects of folate status and the MTHFR 677T mutation on the M+1 enrichment in nucleotides from [13C] - labeled serine precursor………………………..62

Table 4. Effects of folate status on overall homocysteine remethylation in protein and cytoplasma amino acids pools. Data are presented as methionine enrichments (M+4 / M+5) from the [13C5] - labeled methionine precursor……………....63

Table 5. Effect folate status and the MTHFR 677T mutation on methionine enrichments from the [13C5] - labeled methionine precursor in protein and cytoplasmic amino acids pools in transformed lymphoblasts. Data were calculated from the M+4 and M+5 methionine species………………………………………………..64

Table 6. Effects of folate status and MTHFR 677T mutation on folate dependent homocysteine remethylation in protein and cytoplasmic amino acids pools in transformed lymphoblasts. Data were calculated as the M+1 methionine specie from the [13C] - labeled serine precursor…………………………………..65

Table 7. Effects of folate status on intracellular contents of adoMet, adoHcy, adoMet / adoHcy ratio, and the percentage of genome-wide 5-methyl cytidine in transformed lymphoblasts……………………………………………...….66

References…………………………………………………………………67

Reference List

1. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat.Genet. 1995;10:111-3.
2. Nishio H, Lee MJ, Fujii M et al. A common mutation in methylenetetrahydrofolate reductase gene among the Japanese population. Jpn.J Hum.Genet. 1996;41:247-51.
3. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am.J Hum.Genet. 1988;43:414-21.
4. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation 1996;94:1812-4.
5. Skibola CF, Smith MT, Kane E et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc.Natl.Acad.Sci.U.S.A 1999;96:12810-5.
6. Ma J, Stampfer MJ, Giovannucci E et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997;57:1098-102.
7. Matsuo K, Hamajima N, Suzuki R et al. Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol. 2004;77:351-7.
8. Matsuo K, Suzuki R, Hamajima N et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001;97:3205-9.
9. Matsuo K, Suzuki R, Hamajima N et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001;97:3205-9.
10. Skibola CF, Smith MT, Hubbard A et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002;99:3786-91.
11. Skibola CF, Smith MT, Kane E et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc.Natl.Acad.Sci.U.S.A 1999;96:12810-5.
12. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am.J Hum.Genet. 1988;43:414-21.
13. Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc.Natl.Acad.Sci.U.S.A 2001;98:14853-8.
14. James SJ, Miller BJ, Basnakian AG, Pogribny IP, Pogribna M, Muskhelishvili L. Apoptosis and proliferation under conditions of deoxynucleotide pool imbalance in liver of folate/methyl deficient rats. Carcinogenesis 1997;18:287-93.
15. Matsuo K, Hamajima N, Suzuki R et al. Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol. 2004;77:351-7.
16. Heijmans BT, Boer JM, Suchiman HE et al. A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res. 2003;63:1249-53.
17. Chiusolo P, Reddiconto G, Casorelli I et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann.Oncol. 2002;13:1915-8.
18. Ulrich CM, Yasui Y, Storb R et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231-4.
19. Ulrich CM, Yasui Y, Storb R et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231-4.
20. van Ede AE, Laan RF, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 2001;44:2525-30.
21. Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-90.
22. Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004;14:785-92.
23. Lu JW, Gao CM, Wu JZ, Sun XF, Wang L, Feng JF. [Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma]. Ai.Zheng. 2004;23:958-62.
24. Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004;14:785-92.
25. Lathrop SL, Shane B, Bagley PJ, Nadeau M, Shih V, Selhub J. Combined marginal folate and riboflavin status affect homocysteine methylation in cultured immortalized lymphocytes from persons homozygous for the MTHFR C677T mutation. J.Nutr. 2003;133:2716-20.
26. Selhub J, Seyoum E, Pomfret EA, Zeisel SH. Effects of choline deficiency and methotrexate treatment upon liver folate content and distribution. Cancer Res. 1991;51:16-21.
27. Quinlivan EP, Davis SR, Shelnutt KP et al. Methylenetetrahydrofolate reductase 677C->T polymorphism and folate status affect one-carbon incorporation into human DNA deoxynucleosides. J Nutr. 2005;135:389-96.
28. Stern LL, Mason JB, Selhub J, Choi SW. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol.Biomarkers Prev. 2000;9:849-53.
29. Herbig K, Chiang EP, Lee LR, Hills J, Shane B, Stover PJ. Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. J.Biol.Chem. 2002;277:38381-9.
30. Fell D, Benjamin LE, Steele RD. Determination of adenosine and S-adenosyl derivatives of sulfur amino acids in rat liver by high-performance liquid chromatography. J.Chromatogr. 1985;345:150-6.
31. Mudd SH, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism 1975;24:721-35.
32. Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004;14:785-92.
33. Lathrop SL, Shane B, Bagley PJ, Nadeau M, Shih V, Selhub J. Combined marginal folate and riboflavin status affect homocysteine methylation in cultured immortalized lymphocytes from persons homozygous for the MTHFR C677T mutation. J.Nutr. 2003;133:2716-20.
34. Fowler B, Whitehouse C, Wenzel F, Wraith JE. Methionine and serine formation in control and mutant human cultured fibroblasts: evidence for methyl trapping and characterization of remethylation defects. Pediatr.Res. 1997;41:145-51.
35. Fell D, Selhub J. Disruption of thymidylate synthesis and glycine-serine interconversion by L-methionine and L-homocystine in Raji cells. Biochim.Biophys.Acta 1990;1033:80-4.
36. Green JM, MacKenzie RE, Matthews RG. Substrate flux through methylenetetrahydrofolate dehydrogenase: predicted effects of the concentration of methylenetetrahydrofolate on its partitioning into pathways leading to nucleotide biosynthesis or methionine regeneration. Biochemistry 1988;27:8014-22.
37. Matsuo K, Suzuki R, Hamajima N et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001;97:3205-9.
38. Stankova J, Shang J, Rozen R. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo. Clin.Cancer Res. 2005;11:2047-52.
39. van Triest B, Pinedo HM, van Hensbergen Y et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin.Cancer Res. 1999;5:643-54.
40. Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004;14:785-92.
41. Yawata A, Kim SR, Miyajima A et al. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Cancer Chemother.Pharmacol. 2005.
42. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J.Natl.Cancer Inst. 2004;96:134-44.
43. Yawata A, Kim SR, Miyajima A et al. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Cancer Chemother.Pharmacol. 2005.
44. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int.J Mol.Med. 2003;11:593-600.

45. Lu S, Chen GL, Ren C, Kwabi-Addo B, Epner DE. Methionine restriction selectively targets thymidylate synthase in prostate cancer cells. Biochem.Pharmacol. 2003;66:791-800.
46. Townsend JH, Davis SR, Mackey AD, Gregory JF, III. Folate deprivation reduces homocysteine remethylation in a human intestinal epithelial cell culture model: role of serine in one-carbon donation. Am.J.Physiol Gastrointest.Liver Physiol 2004;286:G588-G595.
47. Davis SR, Quinlivan EP, Shelnutt KP et al. Homocysteine synthesis is elevated but total remethylation is unchanged by the methylenetetrahydrofolate reductase 677C->T polymorphism and by dietary folate restriction in young women. J Nutr. 2005;135:1045-50.